直肠癌放射治疗:ASTRO临床实践指南重点更新
美国放射肿瘤学会(ASTRO)召集多学科工作组,基于系统文献综述更新可手术直肠癌新辅助放疗适应证、方案选择及非手术治疗或局部切除适应证三个关键问题。指南强烈推荐II-III期直肠癌行新辅助放疗,对局部区域复发低危患者条件性推荐可考虑省略放疗;T3-T4期和淋巴结阳性患者强烈推荐全程新辅助治疗(TNT)。
要点
- II-III期直肠癌强烈推荐新辅助放疗;局部区域复发低危者可考虑省略放疗。
- T3-T4期和淋巴结阳性直肠癌强烈推荐TNT;高危者强烈推荐化疗置于长程放化疗前或后。
- 以非手术治疗为优先者,强烈推荐同步放化疗后巩固化疗。
核心结论
- 工作组提出推荐以指导直肠癌放疗的最佳临床实践,重点强调多学科诊疗。
- 未来研究应进一步探讨最佳治疗方案,以实现基于个体风险分层和生活质量优先级的更个体化推荐。
研究设计与样本
- ASTRO召集多学科工作组,基于系统文献综述,采用预设共识构建方法和证据质量分级与推荐强度系统制定推荐。
- 更新3个关键问题:新辅助放疗适应证、新辅助方案选择、根治性/术前放化疗后考虑非手术治疗或局部切除的适应证。
主要发现
- II-III期直肠癌患者强烈推荐新辅助放疗。
- 局部区域复发低危患者条件性推荐可考虑省略新辅助放疗,倾向于新辅助化疗且治疗反应良好或直接手术。
- T3-T4期和淋巴结阳性直肠癌接受新辅助放疗者强烈推荐TNT。
- 局部区域复发高危患者强烈推荐TNT且化疗置于长程放化疗前或后;条件性推荐TNT采用短程放疗后化疗。
- 以非手术治疗为优先的直肠癌患者强烈推荐同步放化疗后巩固化疗。
关键数值与推荐
- II-III期直肠癌:强烈推荐新辅助放疗。
- 局部区域复发低危:条件性推荐可考虑省略新辅助放疗,倾向于新辅助化疗且治疗反应良好或直接手术。
- T3-T4期和淋巴结阳性接受新辅助放疗:强烈推荐TNT。
- 局部区域复发高危:强烈推荐TNT且化疗置于长程放化疗前或后;条件性推荐TNT采用短程放疗后化疗。
- 以非手术治疗为优先:强烈推荐同步放化疗后巩固化疗。
临床怎么用
- 放疗剂量分割方案选择、治疗顺序及非手术治疗考虑应由多学科共识决定,并基于疾病范围、疾病位置、患者偏好和生活质量考虑。
- 原文未据此给出其他推荐。
局限性
- 未来研究应聚焦进一步探讨最佳治疗方案,以实现基于个体风险分层和生活质量优先级的更个体化推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation. RESULTS: For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node-positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus and based on disease extent, disease location, patient preferences, and quality of life considerations. CONCLUSIONS: The task force proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.
引用
- Wo JY, Ashman JB, Bhadkamkar NA, et al. Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update. Pract Radiat Oncol. 2024. PMID: 39603501. doi:10.1016/j.prro.2024.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。